Agouti-related peptide
AgRP (agouti-related peptide) is a neuropeptide produced by orexigenic neurons in the ventromedial arcuate nucleus of the hypothalamus, where it is co-expressed with NPY and GABA as a triply co-expressing population that constitutes one of the most powerful hunger-driving circuits in the mammalian brain. Its mechanism is precise: AgRP acts as an inverse agonist at melanocortin-4 receptor (MC4R), not merely blocking the satiety signal of α-MSH but actively suppressing MC4R’s constitutive activity below its baseline, driving orexigenic signalling even in the absence of competing melanocortin ligands. AgRP neuron activity is tightly regulated by fasting, ghrelin, leptin, and insulin, making these neurons a direct intracellular readout of the body’s metabolic state. Separately, AgRP belongs to the agouti protein family whose peripheral member – agouti-signalling protein (ASIP) – acts at MC1R in melanocytes to shift melanin production from photoprotective eumelanin toward UV-sensitive phaeomelanin, giving AgRP a cross-domain relevance in the aesthetics knowledge base that extends beyond appetite biology.
AgRP occupies a specific and distinct position in hypothalamic appetite regulation – not because it does something entirely different from NPY, with which it is always co-expressed, but because it does something complementary over a different timescale. NPY drives rapid, immediate appetite by acting on Y1 and Y5 receptors; AgRP drives a longer, more sustained food-seeking state by antagonising the melanocortin satiety pathway at MC3R and MC4R. Both are released from the same neurons simultaneously, but the temporal profiles of their actions are different: NPY’s effect is immediate and transient; AgRP’s is slower in onset but remarkably persistent, with pharmacological administration in animal models producing increased food intake for up to a week after a single dose. [1] Understanding why the afternoon craving can feel so sustained – persisting even after eating – is partly a story about AgRP’s mechanism.
The MC4R Mechanism: Inverse Agonist, Not Just Antagonist
The distinction between AgRP as an inverse agonist and as a simple competitive antagonist matters clinically. MC4R, the receptor at which AgRP primarily acts, possesses constitutive activity – it maintains a degree of baseline signalling even in the absence of its natural agonist α-MSH, and this constitutive activity appears essential for normal body weight maintenance. [6] A competitive antagonist would merely block α-MSH from activating MC4R, reducing the satiety signal without changing the baseline. An inverse agonist does more: it suppresses the constitutive activity itself, driving receptor signalling below its resting state. AgRP is confirmed as an inverse agonist at constitutively active MC4R, meaning that its action is orexigenic through two simultaneous mechanisms – blocking the incoming satiety signal and actively reducing the receptor’s tonic suppression of hunger. [3]
The functional result is that when AgRP neurons fire, the hypothalamic satiety tone drops sharply and durably. This is the neurochemical state that the four-hour post-lunch glucose fall activates: as cellular glucose declines and fat oxidation remains blocked by the earlier insulin spike, AgRP neuron activity rises, MC4R is progressively suppressed, and the subjective experience is an escalating, somewhat aversive hunger signal that AgRP research has independently confirmed carries negative valence. [4] The unpleasantness of a missed afternoon meal is not incidental – it is a design feature. Hunger that feels mildly aversive is hunger that motivates action.
What Activates and Suppresses AgRP Neurons
AgRP and NPY mRNA expression in the arcuate nucleus is tightly calibrated to metabolic state. Fasting markedly increases expression of both; refeeding and hormonal satiety signals suppress their transcription. [2] The specific upstream regulators are:
Activators – ghrelin (the stomach-derived hunger hormone, rising in the pre-prandial state and during energy deficit); low circulating glucose; low leptin (the adipose-derived satiety hormone); cortisol (permissively, at the arcuate level during stress or energy deficit).
Suppressors – leptin (binding to LepRb on AgRP neurons directly suppresses firing); insulin (acting at the arcuate nucleus to suppress AgRP transcription and firing); PYY (released from the gut post-meal, inhibiting AgRP neurons via Y2 receptors); GLP-1 (acting via GLP-1 receptors on arcuate AgRP neurons to reduce their activity, which is a component of GLP-1 agonist medication’s appetite-suppressive effect). [1]
A mechanistically important finding from recent optogenetic and chemogenetic research: acute activation of AgRP neurons produces not only hyperphagia but also systemic insulin resistance, by reprogramming brown adipose tissue gene expression toward a myogenic signature and raising myostatin levels – diverting glucose toward the brain during perceived fuel scarcity. [4] This adaptive mechanism – hunger state → AgRP activation → peripheral insulin resistance – makes biological sense under acute fasting, but creates a compounding problem in chronically activated AgRP states such as leptin resistance and diet-induced obesity, where persistent AgRP neuron firing may contribute to the maintenance of insulin resistance independent of the original dietary trigger.
The ASIP/AgRP Family: The Pigmentation Cross-Link
AgRP belongs to the agouti protein family, defined by a conserved C-terminal cysteine-knot domain (the agouti motif) that confers melanocortin receptor binding. [5] Its peripheral structural and functional homolog is agouti-signalling protein (ASIP), encoded by the ASIP gene and expressed primarily in adipose tissue and skin. While AgRP acts centrally at MC3R and MC4R in the hypothalamus, ASIP acts peripherally at MC1R in melanocytes – and the consequence is a direct switch in melanin production.
When α-MSH binds MC1R, it activates the cAMP/PKA pathway, upregulating MITF, tyrosinase activity, and eumelanin production – the dark, photoprotective pigment. When ASIP displaces α-MSH at MC1R, the cAMP pathway is suppressed, and melanocytes shift their output toward phaeomelanin – lighter, less UV-absorbent, and associated with increased UV sensitivity and photocarcinogenesis risk. In human melanocytes, ASIP specifically blocks α-MSH binding to MC1R, inhibits its effects on tyrosinase activity and cell proliferation, and does so even downstream of the receptor at the cAMP level, confirming the pathway as genuinely competitive rather than allosteric. [7]
The MC1R/ASIP system is therefore the peripheral mirror of the MC4R/AgRP system: in both cases, a melanocortin agonist (α-MSH) drives a physiologically protective output (satiety centrally; eumelanogenesis peripherally), and a member of the agouti family (AgRP centrally; ASIP peripherally) opposes it. The evolutionary connection is not coincidental – pigmentation and energy homeostasis share a common hormonal currency in the melanocortin system.
Clinical Application
AgRP and the Afternoon Hunger Signal
When the postprandial glucose fall activates AgRP/NPY neurons, the NPY component drives the immediate urgency of the craving and the AgRP component sustains it. The inverse agonist mechanism means the satiety tone is not merely reduced – it is actively driven below baseline, and this suppression persists well beyond what the immediate glucose deficit alone would produce. Clients who describe the 4pm craving as disproportionate to their actual hunger at other times of day, or who note that eating something small doesn’t resolve the drive in the afternoon the way it would at other times, are partly describing the temporal mismatch between AgRP’s slow onset and long duration versus the shorter-lived NPY component.
AgRP and GLP-1 Medication
GLP-1 receptor agonists suppress AgRP neuron activity as part of their appetite mechanism – this is well-characterised in both animal and human data. [1] Clients report that hunger signals feel qualitatively different on GLP-1 medication: less urgent, less food-specific, more manageable. The AgRP suppression component is the likely explanation. When medication is reduced or stopped, AgRP neuron activity returns to its pre-treatment level, which – if the underlying metabolic state has not changed – may be chronically elevated due to leptin resistance or habitual dietary patterns that repeatedly activate AgRP firing. The craving returning at the same time of day, with the same urgency, is consistent with AgRP neuron activity resuming its previous pattern once GLP-1 suppression is lifted. This is distinct from habit or psychological dependency; it is the restoration of a neurochemical state that medication was pharmacologically overriding.
ASIP, MC1R, and Pigmentation Conversations
The ASIP/MC1R arm of this entity has limited direct procedural relevance but genuine informational value for practitioners discussing pigmentation biology, photoprotection, and individual UV risk. Clients with MC1R variant genotypes – the red hair/fair skin/freckles phenotype that reflects reduced eumelanin production – are carrying genetically increased ASIP-like MC1R signalling, producing less photoprotective eumelanin and more UV-sensitive phaeomelanin. Their elevated photodamage accumulation and melanoma risk is partly the consequence of reduced α-MSH/MC1R activation relative to ASIP/MC1R – the same receptor balance that AgRP research has mechanistically characterised at the central level. This framing does not change clinical management, but it contextualises the biology of photoprotection in a way that is mechanistically accurate and connects the aesthetic conversation to the broader melanocortin system.
References
Baldini G, Phelan KD (2019). The melanocortin pathway and control of appetite-progress and therapeutic implications. J Endocrinol, 241(1), R1-R33 . doi.org/10.1530/joe-18-0596
Fu Y (2025). Regulation of Feeding Behavior and Body Weight by Orexigenic Neurons in the Arcuate Nucleus. J Obes Metab Syndr, 34(3), 213-223 . doi.org/10.7570/jomes25059
Haskell-Luevano C, Monck EK (2001). Agouti-related protein functions as an inverse agonist at a constitutively active brain melanocortin-4 receptor. Regul Pept, 99(1), 1-7 . doi.org/10.1016/s0167-0115(01)00234-8
Jais A, Brüning JC (2022). Arcuate Nucleus-Dependent Regulation of Metabolism-Pathways to Obesity and Diabetes Mellitus. Endocr Rev, 43(2), 314-328 . doi.org/10.1210/endrev/bnab025
Koerperich ZM, Ericson MD, Freeman KT, et al. (2020). Incorporation of Agouti-Related Protein (AgRP) Human Single Nucleotide Polymorphisms (SNPs) in the AgRP-Derived Macrocyclic Scaffold c[Pro-Arg-Phe-Phe-Asn-Ala-Phe-dPro] Decreases Melanocortin-4 Receptor Antagonist Potency and Results in the Discovery of Melanocortin-5 Receptor Antagonists. J Med Chem, 63(5), 2194-2208 . doi.org/10.1021/acs.jmedchem.9b00860
Smith MA, Hisadome K, Al-Qassab H, et al. (2007). Melanocortins and agouti-related protein modulate the excitability of two arcuate nucleus neuron populations by alteration of resting potassium conductances. J Physiol, 578(Pt 2), 425-38 . doi.org/10.1113/jphysiol.2006.119479
Suzuki I, Tada A, Ollmann MM, et al. (1997). Agouti signaling protein inhibits melanogenesis and the response of human melanocytes to alpha-melanotropin. J Invest Dermatol, 108(6), 838-42 . doi.org/10.1111/1523-1747.ep12292572
Also Known As
- agouti related neuropeptide
- agouti-related neuropeptide
- agouti-related protein
- AgRP
Learn More
This topic is discussed in 1 article:
-
That sudden 4pm carb craving after a proper lunch isn’t a lack of willpower. It’s three biological systems colliding at exactly the wrong moment. Discover the metabolic science behind it and what actually helps.